A Phase 1b Study of SMT C1100 in Subjects With Duchenne Muscular Dystrophy (DMD)
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether increasing doses of SMT C1100 are safe,
well tolerated and achieve appropriate blood levels in patients with Duchenne Muscular
Dystrophy (DMD).